Literature DB >> 18562572

Chemical and biological features of Burkholderia cepacia complex lipopolysaccharides.

Anthony De Soyza1, Alba Silipo, Rosa Lanzetta, John R Govan, Antonio Molinaro.   

Abstract

The Burkholderia cepacia complex comprises 10 closely related Gram-negative organisms all of which appear capable of causing disease in humans. These organisms appear of particular relevance to patients with cystic fibrosis. Lipopolysaccharide (LPS) is an important virulence determinant in Gram-negative pathogens. In this review, we highlight important data within the field commenting on LPS/lipid A structure-to-function relationships and cytokine induction capacity of Burkholderia strains studied so far.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562572     DOI: 10.1177/1753425908093984

Source DB:  PubMed          Journal:  Innate Immun        ISSN: 1753-4259            Impact factor:   2.680


  21 in total

1.  Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex.

Authors:  Karin Bodewits; Christian R H Raetz; John R Govan; Dominic J Campopiano
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

2.  Biocide susceptibility of the Burkholderia cepacia complex.

Authors:  Helen Rose; Adam Baldwin; Christopher G Dowson; Eshwar Mahenthiralingam
Journal:  J Antimicrob Chemother       Date:  2009-01-18       Impact factor: 5.790

3.  Permeability Barrier of Gram-Negative Cell Envelopes and Approaches To Bypass It.

Authors:  Helen I Zgurskaya; Cesar A Löpez; S Gnanakaran
Journal:  ACS Infect Dis       Date:  2015       Impact factor: 5.084

4.  Efficient Synthesis of 4-Amino-4-deoxy-L-arabinose and Spacer-equipped 4-Amino-4-deoxy-L-arabinopyranosides by Transglycosylation Reactions.

Authors:  Bernhard Müller; Markus Blaukopf; Andreas Hofinger; Alla Zamyatina; Helmut Brade; Paul Kosma
Journal:  Synthesis (Stuttg)       Date:  2010-09       Impact factor: 3.157

5.  Insect Gut Symbiont Susceptibility to Host Antimicrobial Peptides Caused by Alteration of the Bacterial Cell Envelope.

Authors:  Jiyeun Kate Kim; Dae Woo Son; Chan-Hee Kim; Jae Hyun Cho; Roberta Marchetti; Alba Silipo; Luisa Sturiale; Ha Young Park; Ye Rang Huh; Hiroshi Nakayama; Takema Fukatsu; Antonio Molinaro; Bok Luel Lee
Journal:  J Biol Chem       Date:  2015-06-26       Impact factor: 5.157

6.  In vitro susceptibility of Burkholderia vietnamiensis to aminoglycosides.

Authors:  Agatha N Jassem; James E A Zlosnik; Deborah A Henry; Robert E W Hancock; Robert K Ernst; David P Speert
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

7.  Short Palate, Lung, and Nasal Epithelial Clone 1 Has Antimicrobial and Antibiofilm Activities against the Burkholderia cepacia Complex.

Authors:  Saira Ahmad; Jean Tyrrell; William G Walton; Ashutosh Tripathy; Matthew R Redinbo; Robert Tarran
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

8.  The lipopolysaccharide core oligosaccharide of Burkholderia plays a critical role in maintaining a proper gut symbiosis with the bean bug Riptortus pedestris.

Authors:  Jiyeun Kate Kim; Ho Am Jang; Min Seon Kim; Jae Hyun Cho; Junbeom Lee; Flaviana Di Lorenzo; Luisa Sturiale; Alba Silipo; Antonio Molinaro; Bok Luel Lee
Journal:  J Biol Chem       Date:  2017-09-25       Impact factor: 5.157

9.  Exploring the metabolic network of the epidemic pathogen Burkholderia cenocepacia J2315 via genome-scale reconstruction.

Authors:  Kechi Fang; Hansheng Zhao; Changyue Sun; Carolyn M C Lam; Suhua Chang; Kunlin Zhang; Gurudutta Panda; Miguel Godinho; Vítor A P Martins dos Santos; Jing Wang
Journal:  BMC Syst Biol       Date:  2011-05-25

10.  Synthesis of Neoglycoconjugates Containing 4-Amino-4-deoxy-l-arabinose Epitopes Corresponding to the Inner Core of Burkholderia and Proteus Lipopolysaccharides.

Authors:  Markus Blaukopf; Bernhard Müller; Andreas Hofinger; Paul Kosma
Journal:  European J Org Chem       Date:  2011-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.